Press Release

Loebsack Legislation to Create National, Coordinated Response to Diabetes Signed into Law

Signing coincides with American Diabetes Month

f t # e
Washington, November 6, 2017 | Joe Hand (202-225-6576) | comments
Congressman Dave Loebsack released the following statement today after President Trump signed into law S. 920, the National Clinical Care Commission Act. Loebsack and Congressman Pete Olson (R-TX) were the bipartisan cosponsors of the House version of this legislation, which passed by unanimous consent on a voice vote. This legislation will help improve and coordinate a national response to diabetes, and other metabolic and autoimmune diseases, by establishing a private-public Commission charged with making recommendations to streamline federal investments, as well as improving coordination and clinical care outcomes. November is recognized as American Diabetes Month to help raise awareness of the disease.

Video of Loebsack discussing the legislation when it was passed by the House can be found here.

“The signing of the National Clinical Care Commission Act will help bring together the best clinical endocrinologists, specialists and health care professionals in search of a cure for diabetes. This disease affects over 30 million Americans and costs $320 billion each year in health care costs. I thank President Trump for signing this bill into law and look forward to seeing the Commission get set up and begin its important work.”

The commission brings together clinical endocrinologists, specialists, health care professionals, patients and representatives from the federal agencies. Specifically, the National Clinical Care Commission will help improve care by:
•    Identifying gaps where new approaches are needed to improve diabetes care
•    Eliminating duplication and conflicting efforts and assisting in coordination across all federal agencies
•    Leveraging the significant federal investment in public health by evaluating best practices and other resources and tools for diabetes health care professionals and patients
•    Evaluating the utilization and data collection mechanisms of existing programs
•    Providing guidance on diabetes clinical care to maximize the effectiveness of our strong federal investment in diabetes research
f t # e